Table 2.

Blood pressure and heart rates for subjects with hemodynamic effects

Parameter/ criteria [n (%)]	Placebo n = 9	Regadenoson
		100 μg n = 9	200 μg n = 8	400 μg n = 8
Systolic blood pressure
<90 mm Hg	0	3 (33.3)	0	0
≥200 mm Hg	0	0	0	0
Decrease >35 mm Hg	0	2 (22.2)	1 (12.5)	0
Increase ≥115 mm Hg	0	0	0	0
≥80 and increase ≥20 mm Hg	0	0	0	0
Diastolic blood pressure
<50 mm Hg	0	1 (11.1)	0	1 (12.5)
≥115 mm Hg	0	0	0	0
Decrease >25 mm Hg	0	1 (11.1)	1 (12.5)	0
Increase ≥30 mm Hg	0	0	0	0
Heart rate
≥100 bpm	0	3 (33.3)	7 (87.5)	6 (75.0)
Increase >40 bpm	0	2 (22.2)	4 (50.0)	7 (87.5)

All data from the pharmacodynamic population